1. UBTF tandem duplications in pediatric myelodysplastic syndrome and acute myeloid leukemia: implications for clinical screening and diagnosis.
- Author
-
Barajas JM, Umeda M, Contreras L, Khanlari M, Westover T, Walsh MP, Xiong E, Yang C, Otero B, Arribas-Layton M, Abdelhamed S, Song G, Ma X, Thomas Rd ME, Ma J, and Klco JM
- Subjects
- Humans, Child, Male, Child, Preschool, Female, Adolescent, Tandem Repeat Sequences genetics, Infant, Mutation, Exons genetics, Transcription Factors genetics, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes pathology, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute pathology, Gene Duplication
- Abstract
Recent genomic studies in adult and pediatric acute myeloid leukemia (AML) demonstrated recurrent in-frame tandem duplications (TD) in exon 13 of upstream binding transcription factor (UBTF). These alterations, which account for approximately 4.3% of AML in childhood and about 3% in adult AML aged <60 years of age, are subtype-defining and associated with poor outcomes. Here, we provide a comprehensive investigation into the clinicopathological features of UBTF-TD myeloid neoplasms in childhood, including 89 unique pediatric AML and 6 myelodysplastic syndrome (MDS) cases harboring a tandem duplication in exon 13 of UBTF. We demonstrate that UBTF-TD myeloid tumors are associated with dysplastic features, low bone marrow blast infiltration, and low white blood cell count. Furthermore, using bulk and single-cell analyses, we confirm that UBTF-TD is an early and clonal event associated with a distinct transcriptional profile, whereas the acquisition of FLT3 or WT1 mutations is associated with more stem cell-like programs. Lastly, we report rare duplications within exon 9 of UBTF that phenocopy exon 13 duplications, expanding the spectrum of UBTF alterations in pediatric myeloid tumors. Collectively, we comprehensively characterize pediatric AML and MDS with UBTF-TD, and highlight key clinical and pathologic features that distinguish this new entity from other molecular subtypes of AML.
- Published
- 2024
- Full Text
- View/download PDF